{
    "@context": {
        "schema": "https://schema.org/",
        "dct": "http://purl.org/dc/terms/",
        "hg": "https://hormuz.group/data/ns#"
    },
    "id": "hg:company:tamin-pharmaceutical-investment-company",
    "identifier": "hg:company:tamin-pharmaceutical-investment-company",
    "dataset_type": "entity_dataset",
    "entity_type": "company",
    "data_version": "2.0",
    "generated_by": "Hormuz Data Layer 0.2.1",
    "generated_at": "2026-07-04T02:51:16+00:00",
    "name": "Tamin Pharmaceutical Investment Company",
    "slug": "tamin-pharmaceutical-investment-company",
    "status": "publish",
    "url": "https://hormuz.group/companies/tamin-pharmaceutical-investment-company/",
    "json_url": "https://hormuz.group/wp-content/uploads/hormuz-data/cpt/company/tamin-pharmaceutical-investment-company.json",
    "rest_url": "https://hormuz.group/wp-json/hormuz-data/v1/cpt/company/tamin-pharmaceutical-investment-company",
    "summary": "",
    "machine_summary": "Tamin Pharmaceutical Investment Company Tamin Pharmaceutical Investment Company, widely associated with TPICO, is a major Tehran-based pharmaceutical holding in Iran’s healthcare and capital-market landscape. Its relevance comes from portfolio exposure across pharmaceutical production, distribution, raw materials, and healthcare supply networks. For Hormuz Group, TPICO is useful as a sector-level lens on medicine availability, import substitution, regulated pricing, public-market disclosure, and the role of large holdings in organizing Iran’s pharmaceutical economy. In the Hormuz investment graph, Tamin Pharmaceutical Investment Company connects healthcare demand, listed capital, pharmaceutical manufacturing, raw-material access, distribution networks, and supply-shortage risk. It is useful for screening pharma-sector concentration, mapping subsidiary exposure, evaluating import-dependence pressure, and identifying where regulated pricing, domestic production, and medicine availability intersect. Foreign-facing analysis should verify current portfolio composition, subsidiary operations, disclosure data, procurement dependencies, sanctions exposure, compliance rules, and counterparty quality before commercial use. Tamin Pharmaceutical Investment Company is a pharmaceutical investment holding with exposure to drug manufacturing, active pharmaceutical ingredients, distribution, medical and healthcare-related products, and sector-level portfolio management. Its activity connects capital allocation, healthcare demand, pharmaceutical supply chains, regulated medicine markets, import-dependent inputs, and listed healthcare-sector exposure. province: Tehran industry: Financial Services, Healthcare & Pharma, Pharmaceuticals market: Capital Markets, Consumer Demand, Healthcare, Supply Chains challenges: Compliance, Import Dependence, Supply Shortage, Technology Gap company_type: Holding Company, Public Company city: Tehran",
    "published_at": "2026-06-28T18:12:53+00:00",
    "modified_at": "2026-06-28T18:12:53+00:00",
    "taxonomies": {
        "province": [
            {
                "id": 3,
                "name": "Tehran",
                "slug": "tehran",
                "url": "https://hormuz.group/provinces/tehran/"
            }
        ],
        "industry": [
            {
                "id": 22,
                "name": "Financial Services",
                "slug": "financial-services",
                "url": "https://hormuz.group/industry/financial-services/"
            },
            {
                "id": 21,
                "name": "Healthcare & Pharma",
                "slug": "healthcare-pharma",
                "url": "https://hormuz.group/industry/healthcare-pharma/"
            },
            {
                "id": 121,
                "name": "Pharmaceuticals",
                "slug": "pharmaceuticals",
                "url": "https://hormuz.group/industry/healthcare-pharma/pharmaceuticals/"
            }
        ],
        "market": [
            {
                "id": 31,
                "name": "Capital Markets",
                "slug": "capital-markets",
                "url": "https://hormuz.group/market/capital-markets/"
            },
            {
                "id": 34,
                "name": "Consumer Demand",
                "slug": "consumer-demand",
                "url": "https://hormuz.group/market/consumer-demand/"
            },
            {
                "id": 69,
                "name": "Healthcare",
                "slug": "healthcare",
                "url": "https://hormuz.group/market/consumer-demand/healthcare/"
            },
            {
                "id": 76,
                "name": "Supply Chains",
                "slug": "supply-chains",
                "url": "https://hormuz.group/market/enterprise-demand/supply-chains/"
            }
        ],
        "challenges": [
            {
                "id": 164,
                "name": "Compliance",
                "slug": "compliance",
                "url": "https://hormuz.group/challenges/regulatory-barriers/compliance/"
            },
            {
                "id": 176,
                "name": "Import Dependence",
                "slug": "import-dependence",
                "url": "https://hormuz.group/challenges/market-gaps/import-dependence/"
            },
            {
                "id": 177,
                "name": "Supply Shortage",
                "slug": "supply-shortage",
                "url": "https://hormuz.group/challenges/market-gaps/supply-shortage/"
            },
            {
                "id": 179,
                "name": "Technology Gap",
                "slug": "technology-gap",
                "url": "https://hormuz.group/challenges/market-gaps/technology-gap/"
            }
        ],
        "company_type": [
            {
                "id": 305,
                "name": "Holding Company",
                "slug": "holding-company",
                "url": "https://hormuz.group/company-type/holding-company/"
            },
            {
                "id": 306,
                "name": "Public Company",
                "slug": "public-company",
                "url": "https://hormuz.group/company-type/public-company/"
            }
        ],
        "city": [
            {
                "id": 384,
                "name": "Tehran",
                "slug": "tehran",
                "url": "https://hormuz.group/cities/tehran/"
            }
        ]
    },
    "taxonomy_labels": {
        "province": "Tehran",
        "industry": "Financial Services, Healthcare & Pharma, Pharmaceuticals",
        "market": "Capital Markets, Consumer Demand, Healthcare, Supply Chains",
        "challenges": "Compliance, Import Dependence, Supply Shortage, Technology Gap",
        "company_type": "Holding Company, Public Company",
        "city": "Tehran"
    },
    "fields_summary": {
        "legal_name": "Tamin Pharmaceutical Investment Company",
        "website": "http://www.tpicoholding.com",
        "city": "Tehran, Tehran Province, Iran",
        "ticker_symbol": "تیپیکو",
        "listing_status": "listed_tse",
        "products_services": "Tamin Pharmaceutical Investment Company is a pharmaceutical investment holding with exposure to drug manufacturing, active pharmaceutical ingredients, distribution, medical and healthcare-related products, and sector-level portfolio management. Its activity connects capital allocation, healthcare demand, pharmaceutical supply chains, regulated medicine markets, import-dependent inputs, and listed healthcare-sector exposure.",
        "export_relevance": "medium",
        "short_profile": "Tamin Pharmaceutical Investment Company, widely associated with TPICO, is a major Tehran-based pharmaceutical holding in Iran’s healthcare and capital-market landscape. Its relevance comes from portfolio exposure across pharmaceutical production, distribution, raw materials, and healthcare supply networks. For Hormuz Group, TPICO is useful as a sector-level lens on medicine availability, import substitution, regulated pricing, public-market disclosure, and the role of large holdings in organizing Iran’s pharmaceutical economy.",
        "investment_relevance": "In the Hormuz investment graph, Tamin Pharmaceutical Investment Company connects healthcare demand, listed capital, pharmaceutical manufacturing, raw-material access, distribution networks, and supply-shortage risk. It is useful for screening pharma-sector concentration, mapping subsidiary exposure, evaluating import-dependence pressure, and identifying where regulated pricing, domestic production, and medicine availability intersect. Foreign-facing analysis should verify current portfolio composition, subsidiary operations, disclosure data, procurement dependencies, sanctions exposure, compliance rules, and counterparty quality before commercial use."
    },
    "fields": {
        "rank_math_internal_links_processed": "1",
        "wp_statistics_words_count": "0",
        "legal_name": "Tamin Pharmaceutical Investment Company",
        "city": "Tehran, Tehran Province, Iran",
        "ticker_symbol": "تیپیکو",
        "export_relevance": "medium",
        "verification_status": "basic",
        "data_confidence": "high",
        "listing_status": "listed_tse",
        "last_updated": "28/06/2026",
        "website": "http://www.tpicoholding.com",
        "products_services": "Tamin Pharmaceutical Investment Company is a pharmaceutical investment holding with exposure to drug manufacturing, active pharmaceutical ingredients, distribution, medical and healthcare-related products, and sector-level portfolio management. Its activity connects capital allocation, healthcare demand, pharmaceutical supply chains, regulated medicine markets, import-dependent inputs, and listed healthcare-sector exposure.",
        "short_profile": "Tamin Pharmaceutical Investment Company, widely associated with TPICO, is a major Tehran-based pharmaceutical holding in Iran’s healthcare and capital-market landscape. Its relevance comes from portfolio exposure across pharmaceutical production, distribution, raw materials, and healthcare supply networks. For Hormuz Group, TPICO is useful as a sector-level lens on medicine availability, import substitution, regulated pricing, public-market disclosure, and the role of large holdings in organizing Iran’s pharmaceutical economy.",
        "investment_relevance": "In the Hormuz investment graph, Tamin Pharmaceutical Investment Company connects healthcare demand, listed capital, pharmaceutical manufacturing, raw-material access, distribution networks, and supply-shortage risk. It is useful for screening pharma-sector concentration, mapping subsidiary exposure, evaluating import-dependence pressure, and identifying where regulated pricing, domestic production, and medicine availability intersect. Foreign-facing analysis should verify current portfolio composition, subsidiary operations, disclosure data, procurement dependencies, sanctions exposure, compliance rules, and counterparty quality before commercial use.",
        "source_note": "Based on public company, market, sector, and disclosure-related information. Further verification is required before treating this profile as verified investment intelligence."
    },
    "field_profile": {
        "rank_math_internal_links_processed": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "wp_statistics_words_count": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "legal_name": {
            "type": "string",
            "present": true,
            "length": 39
        },
        "city": {
            "type": "string",
            "present": true,
            "length": 29
        },
        "ticker_symbol": {
            "type": "string",
            "present": true,
            "length": 12
        },
        "export_relevance": {
            "type": "string",
            "present": true,
            "length": 6
        },
        "verification_status": {
            "type": "string",
            "present": true,
            "length": 5
        },
        "data_confidence": {
            "type": "string",
            "present": true,
            "length": 4
        },
        "listing_status": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "last_updated": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "website": {
            "type": "string",
            "present": true,
            "length": 27
        },
        "products_services": {
            "type": "string",
            "present": true,
            "length": 427
        },
        "short_profile": {
            "type": "string",
            "present": true,
            "length": 536
        },
        "investment_relevance": {
            "type": "string",
            "present": true,
            "length": 659
        },
        "source_note": {
            "type": "string",
            "present": true,
            "length": 175
        }
    },
    "sources": [
        {
            "type": "note",
            "value": "Based on public company, market, sector, and disclosure-related information. Further verification is required before treating this profile as verified investment intelligence."
        }
    ],
    "quality": {
        "required_fields": [
            "legal_name",
            "website",
            "city",
            "listing_status",
            "products_services",
            "export_relevance",
            "verification_status",
            "data_confidence",
            "short_profile",
            "investment_relevance",
            "source_note",
            "last_updated"
        ],
        "missing_required_fields": [],
        "missing_required_count": 0,
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "28/06/2026",
        "stale_over_180_days": false,
        "quality_score": 100
    },
    "verification": {
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "28/06/2026"
    }
}